MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too
Executive Summary
Emerging Company Profile: Calling itself the most advanced microbiome company focused on skin diseases, MatriSys has advanced a proprietary microbe to Phase IIa for atopic dermatitis. The biotech also is eyeing UV-induced cancer, rosacea, acne, psoriasis and bacterial skin infections.
You may also be interested in...
Ferring Leapfrogs Into Late-Stage Microbiome Race With Rebiotix Buy
The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.
JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis
Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.
Pfizer’s Eucrisa Approval By FDA Adds New Dermatology Anchor
Pfizer’s Eucrisa is one of the first new drugs to launch for the treatment of atopic dermatitis in more than a decade. The launch reflects an expansion strategy by Pfizer to move into a new therapeutic area – dermatology.